Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Decreases By 25.0%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 35,100 shares, a decline of 25.0% from the November 30th total of 46,800 shares. Approximately 1.9% of the company’s stock are short sold. Based on an average daily volume of 46,100 shares, the days-to-cover ratio is currently 0.8 days.

Avenue Therapeutics Stock Performance

Shares of NASDAQ ATXI opened at $1.94 on Friday. The company has a market cap of $3.98 million, a PE ratio of 0.11 and a beta of -0.20. The business has a 50-day simple moving average of $2.00 and a two-hundred day simple moving average of $2.56. Avenue Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $26.47.

Institutional Investors Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC acquired a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned about 7.97% of Avenue Therapeutics as of its most recent SEC filing. 17.34% of the stock is currently owned by institutional investors and hedge funds.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.